William Young - Vertex Pharmaceuticals Independent Director

VRTX -- USA Stock  

Quarterly Earning Report: October 23, 2019  

  Director
Mr. William D. Young is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Young is a Senior Advisor with Blackstone Life Sciences . Mr. Young joined Clarus Ventures, a life sciences VC firm, in 2010. Prior to Clarus Ventures, Mr. Young served from 1999 until June 2009 as the Chairman and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company acquired by Laboratory Corporationrationration of America in June 2009. From 1980 to 1999, Mr. Young was employed at Genentech, Inc. in positions of increasing responsibility, including as Chief Operating Officer from 1997 to 1999, where he was responsible for all product development, manufacturing and commercial functions. Prior to joining Genentech, Mr. Young was with Eli Lilly Co. for 14 years. Mr. Young currently serves as the Chairman of the Board of Directors of NanoString Technologies, Inc., and as a member of the Board of Directors of Theravance BioPharma Inc. Mr. Young retired from BioMarin Pharmaceutical Inc.s Board of Directors in November 2015 and as Biogens Chairman of the Board in June 2014. Mr. Young holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from Indiana University and an Honorary Doctorate in Engineering from Purdue University. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology.
Age: 73  Director Since 2014  MBA    
617 341-6100  www.vrtx.com
Young earned a BS in Chemical Engineering from Purdue University, an M.B.A. from Indiana University and an Honorary Doctorate in Engineering from Purdue University. In 1993, Mr. Young was elected to the National Academy of Engineering for his contributions to biotechnology.

William Young Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95 M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Gary CohenPerrigo Company Plc
2009
Bruce CarterDr Reddys Laboratories Ltd
2008
Larry CordellOrigin Agritech Limited
2012
Christine PoonRegeneron Pharmaceuticals
2010
Laurie BrlasPerrigo Company Plc
2016
Arthur RyanRegeneron Pharmaceuticals
2003
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
Michael BrownRegeneron Pharmaceuticals
1991
Rolf ClassonPerrigo Company Plc
2017
Allan ObermanDr Reddys Laboratories Ltd
2019
Geoffrey ParkerPerrigo Company Plc
2016
Ashok GangulyDr Reddys Laboratories Ltd
2009
Linda RhodesZoetis
2017
Charles BakerRegeneron Pharmaceuticals
N/A
Yingqi XiaOrigin Agritech Limited
2010
Bradley AlfordPerrigo Company Plc
2017
Theodore SamuelsPerrigo Company Plc
2017
Jeffrey KindlerPerrigo Company Plc
2017
Anthony ColesRegeneron Pharmaceuticals
2017
Anupam PuriDr Reddys Laboratories Ltd
2002
Paul BisaroZoetis
2015

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased a lot of shares of
few hours ago
Traded for 152.08
Purchased over 70 shares of
few hours ago
Traded for 35.0
Purchased few shares of
few hours ago
Traded for 177.94
Also please take a look at World Market Map. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.
Search macroaxis.com